Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116077 · ClinicalTrials.gov registry record
Dopamine Receptor Imaging in Mood Disorders
A clinical trial, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 145
- Enrollment target
NCT00116077: Completed study, sponsored by National Institute of Mental Health (NIMH).
NCT00116077 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116077 has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
This study seeks to increase the understanding of dopamine receptor function in the brain during major depressive disorder and bipolar depression, as well as genetic changes that may be behind changes in those receptors' actions. Dopamine is a natural messenger in the brain, involved in reward, motivation, and mood. Volunteers aged 18 to 55 who have primary major depressive disorder and those who have bipolar depression (20 in each group), who are not HIV positive and do not have AIDS, and who are not pregnant or breastfeeding may be eligible for this study. A telephone interview will be held, for patients to answer standardized questions about psychiatric or medical symptoms they may have experienced during their lifetime. Those eligible for the study will undergo interviews and laboratory tests. A psychiatric interview and clinical assessment will collect various data. Patients will undergo the following procedures and tests: * A brief neurological examination * A one-minute electrocardiogram to measure electrical activity of the heart. * Laboratory tests measuring several substances in the blood and urine. * Pregnancy test. A magnetic resonance imaging (MRI) scan will be done to create an image of the volunteer's brain structure. The technique of MRI uses a strong magnetic field and radio waves to obtain images of body organs and tissues. During the MRI scan, volunteers will lie still on a table that will slide into the scanner for 30 minutes and in some cases up to but no more than 90 minutes. Volunteers will be asked to lie as still as possible during the procedure. Then a PET system will create two images of brain blood flow-one of brain dopamine 1 receptor and one of dopamine 2/3 receptor binding. Volunteers will be given a radiotracer, a tiny amount of a drug that can be detected by a special camera in the PET scanner. A tiny flexible tube will be placed in the vein of one arm during each PET scan but during the MRI scan. Volunteers will be asked to lie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2005-06-21 |
| Est. Completion | 2010-11-12 |
What the finished NCT00116077 record still lists
NCT00116077 is an observational study that tracks outcomes without assigning an intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00116077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00116077 about?
NCT00116077 is a clinical study titled "Dopamine Receptor Imaging in Mood Disorders". This study seeks to increase the understanding of dopamine receptor function in the brain during major depressive disorder and bipolar depression, as well as genetic changes that may be behind changes in those receptors' actions. Dopamine is a natural messenger in the brain, involved in reward, moti...
What is the current status of trial NCT00116077?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2005-06-21. Estimated completion is 2010-11-12.
Who is sponsoring clinical trial NCT00116077?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI